# Abcuro Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abcuro - Industry: Biotechnology - Headquarters: Newton, US - Website: www.abcuro.com - Total disclosed funding: $255M - Latest round: Series D (Aug 7, 2026) - Investors on record: 21 ## About Based in the US, Abcuro, Inc. is a biotechnology company focused on developing innovative therapies targeting autoimmune diseases and cancers through the modulation of cytotoxic T cells. Abcuro, Inc., founded in 2015 and headquartered in Newton, US, is dedicated to advancing treatments for autoimmune diseases and cancer. In August 2026, Abcuro, Inc. raised USD 39.383 million in series D funding led by New Leaf Venture Partners, with participation from Bain Capital, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax Venture Capital, Sanofi Ventures, Foresite Capital, New Enterprise Associates, Eurofarma Ventures, Kaitai Capital, Soleus Capital, and Rock Springs Capital. The company was co-founded by Stefano Gullà and Steven Greenberg and is currently led by CEO Alex Martin. Abcuro, Inc. specializes in developing breakthrough therapies for autoimmune diseases and cancer, focusing on the modulation of cytotoxic T cells. Its lead product candidate, ulviprubart, is an investigational monoclonal antibody designed to selectively deplete highly cytotoxic T cells by targeting the killer cell lectin-like receptor G1 (KLRG1). This product aims to address critical medical needs in conditions such as inclusion body myositis, T Cell Large Granular Lymphocytic Leukemia, and certain T and NK cell lymphomas, where cytotoxic T cells contribute to chronic tissue damage or malignancy. Abcuro's products are primarily aimed at healthcare providers, hospitals, and specialized clinics in North America and select European markets, focusing on patients suffering from rare diseases and cancers with limited treatment options. Abcuro's revenue model is structured around business-to-business transactions, partnering with healthcare institutions and pharmaceutical companies. Revenue is generated through the development and potential commercialization of ulviprubart, designed for rare diseases and cancers. Collaborations may involve co-development or licensing agreements, generating income through upfront payments, milestones, and royalties on product sales. By collaborating with healthcare providers and specialty pharmacies, Abcuro establishes a distribution network to enhance access to its therapies. As ulviprubart progresses through clinical trials to market approval, the revenue structure will evolve to include sales of the therapeutic agent, targeting hospitals and specialty clinics managing complex and rare conditions.In February 2025, Abcuro, Inc. raised USD 80.00 mn in Series C funding, which will be utilized to accelerate the licensing process for its muscle ulviprubart product. The company plans to use the August 2026 funding to support a new potentially registrational clinical study of ulviprubart, a monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of patients with less severe Inclusion Body Myositis (IBM). ## Funding rounds - Series D, Aug 7, 2026, $39M — New Enterprise Associates, Bain Capital, Aberdeen Investments, New Leaf Venture Partners, Pontifax Venture Capital, Sanofi Ventures, Mass General Brigham Ventures, Foresite Capital, Redmile Group, Kaitai Capital, RA Capital Management, Rock Springs Capital, Samsara BioCapital, ShangBay Capital, Soleus Capital, Eurofarma Ventures - Series C, Feb 7, 2025, $80M — New Enterprise Associates, Bain Capital, New Leaf Venture Partners, Pontifax Venture Capital, Sanofi Ventures, Mass General Brigham Ventures, Foresite Capital, Redmile Group, RA Capital Management, Samsara BioCapital - Series B, Aug 11, 2023, $120M — Bain Capital, New Leaf Venture Partners, Tekla Capital Management, Pontifax Venture Capital, BlackRock, Sanofi Ventures, Mass General Brigham Ventures, Redmile Group, RA Capital Management, Samsara BioCapital, Soleus Capital, Eurofarma Ventures - Series A, Jan 22, 2021, $7.9M — Pontifax Venture Capital, Sanofi Ventures, RA Capital Management, Partners Healthcare System, Samsara BioCapital, Hongsen Investment - Series A, Nov 9, 2018, $8M — Mass General Brigham Ventures, Kaitai Capital, ShangPharma Innovation ## Investors - Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A, Series B, Series C, Series D - Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series A, Series D - ShangPharma Innovation (https://capitalatlas.ai/funds/shangpharma-innovation) — Series A - Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A, Series B, Series C, Series D - Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A, Series B, Series C, Series D - RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B, Series C, Series D - Partners Healthcare System — Series A - Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A, Series B, Series C, Series D - Hongsen Investment (https://capitalatlas.ai/funds/hongsen-investment) — Series A - Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series B, Series C, Series D - New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B, Series C, Series D - Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series B - BlackRock (https://capitalatlas.ai/funds/blackrock) — Series B - Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B, Series C, Series D - Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series B, Series D - Eurofarma Ventures (https://capitalatlas.ai/funds/eurofarma-ventures) — Series B, Series D - New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series C, Series D - Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C, Series D - Aberdeen Investments (https://capitalatlas.ai/funds/aberdeen-investments) — Series D - Rock Springs Capital — Series D - ShangBay Capital (https://capitalatlas.ai/funds/shangbay-capital) — Series D